Table 3. Biological effects of the EpoFc dimer and EpoFc monomer after pulmonary delivery in cynomolgus monkeys.
| Dose,* μg/kg
|
Reticulocytes
|
|||
|---|---|---|---|---|
| Drug/route | Pretreatment, % | Posttreatment, % | n | |
| EpoFc monomer Pulmonary | 5 | 0.53 ± 0.35 | 2.47 ± 0.38 | 3 |
| 20 | 0.53 ± 0.12 | 3.40 ± 1.24 | 3 | |
| i.v. | 10 | 0.7 | 2.65 | 2 |
| EpoFc dimer Pulmonary | 10 | 0.60 | 1.75 | 2 |
| 20 | 0.55 | 1.75 | 2 | |
| Epogen Pulmonary | 1.8† | 0.93 ± 0.41 | 1.60 ± 0.25 | 3 |
Monkeys received single doses of the EpoFc monomer either by pulmonary administration or i.v. injection. The EpoFc dimer and Epogen were given once by pulmonary administration. Values represent either the mean of two monkeys or mean ± SD where three or more monkeys were used.
*
Lung-deposited dose for pulmonary delivery.
†
Using a conversion factor of 10 ng/unit; equimolar to 5 μg/kg EpoFc monomer.